- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Al B. Benson Discusses Ongoing Work That Could Affect Future NCCN Guidelines
Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.
EP: 1.Pemigatinib: EMA Panel Offers Conditional Nod for Pemigatinib
EP: 2.Dr Al B. Benson on Neoadjuvant Treatment in Hepatobiliary Cancers
EP: 3.NCCN Updates in Bile Duct Cancer Put Focus on Precision Medicine
EP: 4.Dr Michael D’Angelica on the Importance of NCCN Guideline Updates and Progress in Hepatobiliary Cancer
EP: 5.Dr Al B. Benson Discusses Ongoing Work That Could Affect Future NCCN Guidelines
Al B. Benson, MD, FACP, FASCO, chair of the National Comprehensive Cancer Network (NCCN) hepatobiliary cancer guidelines panel, professor of medicine, and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.
Transcript
As you look ahead, what ongoing research do you anticipate will affect the next round of guideline updates?
I think in terms of the work that's ongoing, certainly there's more work looking at subtypes of patients. There are subgroups of patients, for example, with cholangiocarcinoma, including now, the BRAF population, patients with HER2-positive tumors and their ongoing trials. So, I think the identification further subsets, looking at combinations with immunotherapy—whether these are combinations with other immunotherapeutic drugs with, for example, TKIs, or chemotherapy combinations. These are all ideas that are under investigation currently.
DMD Guidance Could Benefit From Update, Experts Say
January 24th 2024MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.
Read More
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
July 7th 2023Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Read More
NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for DLBCL
June 23rd 2023Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma.
Read More
Review Finds EORTC QLQ-MY20 Useful, Robust 25 Years After Development
June 16th 2023The treatment landscape for multiple myeloma has shifted since European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was first developed in 1996.
Read More
ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC
April 27th 2023The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).
Read More
